Navigation Links
Vaccinex, Inc. Announces Award of Key Patent in Europe for its Antibody Discovery Technology (ActivMab(R))
Date:11/30/2007

ROCHESTER, N.Y., Nov. 30 /PRNewswire/ -- Vaccinex, Inc. announced today the award of a key European patent (European Patent No. 1340088) for its antibody discovery technology platform, branded as ActivMab(R) Technology. Vaccinex is using its patented technology to discover and develop new monoclonal antibody therapies, and has advanced four of its lead therapeutic antibodies into pre-clinical drug development.

"This European patent, and related patents already awarded in the United States and elsewhere, underscores the novelty of our discovery technology, which gives Vaccinex important advantages over competitors in the area of therapeutic antibodies," said Dr. Maurice Zauderer, President & CEO. "Vaccinex is leveraging this patented technology in partnerships with established leaders in the antibody market as we continue to build a pipeline of promising antibody therapies."

The market for antibody therapies is estimated at $25 billion in 2007, and is projected to reach $43 billion by 2012. For additional information about Vaccinex, please visit the company's website at http://www.vaccinex.com.

CONTACT:

Raymond Watkins

VP of Operations and Officer

+1-585-271-2700


'/>"/>
SOURCE Vaccinex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 The Market Element LLC, ... strategic alliance with Designing Gig LLC to provide website ... , “Forging this alliance with Designing Gig represents ... can extend a comprehensive, end-to-end, digital solution for our ... execution,” said Chuck Miller, president of The Market Element. ...
(Date:3/26/2015)... Massachusetts and CINCINNATI ... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... a three-year, broad research collaboration for rare diseases. The ... develop novel therapies to treat rare diseases with ... commercialization capabilities with Cincinnati Children,s research expertise. As ...
(Date:3/26/2015)... PAREXEL International Corporation (Nasdaq: ... organization , announced today that the Company ... all of the business assets of privately-owned Quantum ... specialized pharmacovigilance services, based in Chandigarh, India.  ... monitoring, and prevention of adverse effects with ...
(Date:3/26/2015)... "In America," the popular news television program that airs ... by legendary film actor James Earl Jones, has announced that ... segment. , Botany is commonly described as the scientific ... a bit more complicated than that. Scientists and other professionals ... from the smallest bacteria known to man to the largest ...
Breaking Biology Technology:The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... Mass., Jan. 9, 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: ... discovery and development of drugs for the treatment of ... hepatitis C virus (HCV) development pipeline. ... of a phase I clinical trial of the Company,s ...
... 9, 2012 , Collaboration to create ... to active TB, enabling early treatment and disease outbreak prevention ... infectious disease portfolio with development of DNA-/RNA-based test that complements ... , New assay will use whole blood transcription profiling ...
... FRANCISCO, Jan. 7, 2012 Sutro Biopharma, a biopharmaceutical ... pharmaceutical properties, today announced that it has appointed James ... its newly formed scientific advisory board (SAB).  Prof. Wells ... "We have brought together two leading scientific experts in ...
Cached Biology Technology:Idenix Reports Advancement of HCV Development Pipeline 2Idenix Reports Advancement of HCV Development Pipeline 3Idenix Reports Advancement of HCV Development Pipeline 4QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 2QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 3QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 4QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 5QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 6QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 7Sutro Announces Newly Formed Scientific Advisory Board 2Sutro Announces Newly Formed Scientific Advisory Board 3
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... , March 12, 2015 The mascots ... Brenner Children,s Hospital, part of Wake Forest Baptist Medical ... initiative for the 2015 ACC Men,s Basketball Tournament. Young ... with them and getting their autographs. Brenner ... Baptist. It is the only children,s hospital in northwest ...
(Date:3/10/2015)... , March 10, 2015  Continuing its 167-year history ... Hammacher Schlemmer introduces The Eye Scanning Password Authenticator ... granting access to secure websites or sensitive data. ... travelers at international borders, the device has a small ... points of the iris, converting them into an encrypted ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... After every meal, the body must prevent the immune ... researchers report the identity of a nutrient "floodgate" that ... Their findings appear in the May 4, 2007 issue ... , The researchers found that animals lacking a protein ...
... body appears to control whether certain medications, such as ... or in inhalers for asthma, lose their effectiveness over ... the body that controls many functions, including the contraction ... conducted by Duke University Medical Center and Howard Hughes ...
... diabetic patients of the superbug MRSA - by treating ... and his team used green bottle fly larvae to ... with MRSA and found all but one were cured ... than the 28-week duration for the conventional treatment. ...
Cached Biology News:Keeping the immune system from starting a 'food fight' 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 3Maggots rid patients of MRSA 2
A set of five peptides which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: cap, ...
... Pre-tested for optimal ... support the growth of ... for methylcellulose colony-forming assays ... hematopoietic cells. Not suitable ...
... RAW 264. 7 cells were cultured in DMEM ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
Biology Products: